Traci Dantoni

Tofacitinib 5mg or 10mg twice daily showed a consistent safety profile and sustained efficacy over 5 years in long-term extension studies for patients with rheumatoid arthritis, as presented at the 2013 ACR/ARHP Annual Meeting.

At the 2013 ACR/ARHP Annual Meeting, study researchers presented that the investigational, lower-dose diclofenac submicron particle capsules were generally well-tolerated in patients with osteoarthritis.

Regarding knee osteoarthritis pain, intra-articular (IA) treatments were more efficacious than oral treatments possibly because of the integrated IA placebo effect, reported study authors at the 2013 ACR/ARHP Annual Meeting.

At the 2013 ACR/ARHP Annual Meeting, study authors presented that patients with active rheumatoid arthritis (RA) despite methotrexate (MTX), certolizumab pegol (CZP) + MTX maintained reduction in signs and symptoms through 5 years.

Patients with rheumatoid arthritis (RA) on stable DMARD therapy, who have not adequately responded to immediate-release (IR) prednisone with respect to morning stiffness, showed a statistically significant and clinically meaningful improvement in this symptom when switched to delayed-release (DR) prednisone, as presented at the 2013 ACR/ARHP Annual Meeting.

According to data from a meta-analysis, concomitant immunosuppressants given with the studied TNF-inhibitors reduced the effect of anti-drug antibodies, as presented at the 2013 ACR/ARHP Annual Meeting.

At the 2013 ACR/ARHP Annual Meeting, study investigators presented that epratuzumab was associated with sustained improvements in disease activity in patients with moderate-to-severe systemic lupus erythematosus (SLE).

Influenza vaccine immunogenicity is significantly decreased in patients with systemic lupus erythematosus (SLE) compared with healthy controls, a meta-analysis presented during the 2013 ACR/ARHP Annual Meeting has shown.

Pregnant women with rheumatoid arthritis (RA) who received an influenza vaccination had a similar incidence of influenza-like illness compared with women without autoimmune disease, a study presented at the 2013 ACR/ARHP Annual Meeting has found.

A significantly smaller increase in total corticosteroid dose was seen in the belimumab treatment arms than standard therapy alone for patients with systemic lupus erythematosus (SLE), reported study investigators at the 2013 ACR/ARHP Annual Meeting.